XOMA Royalty Corporation has entered into an agreement to acquire Generation Bio Co.
The acquisition includes potential milestone and royalty payments under Generation Bio's collaboration with Moderna.
Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery platform will be part of XOMA Royalty's portfolio.
Acquisition Agreement Details
XOMA Royalty to acquire Generation Bio for $4.2913 per share with additional contingent value rights for certain milestones and royalty payments.
Board Approval
Generation Bio's board unanimously approved the merger agreement with XOMA Royalty after a thorough review process.
Support from Stockholders
Approximately 15% of Generation Bio stockholders have signed support agreements to tender their shares in the Offer and support the merger.
- The acquisition is expected to provide XOMA Royalty with a strategic position in the biotech industry through Generation Bio's innovative delivery platform and collaboration with Moderna.
- XOMA Royalty aims to leverage Generation Bio's technology to enhance its portfolio and potentially benefit from future development and commercial milestones.
The acquisition of Generation Bio by XOMA Royalty marks a significant step towards enhancing XOMA Royalty's biotech portfolio and leveraging Generation Bio's innovative technologies for potential future success in the industry.